Latest Thrombosis Stories
Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014
- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO,
Results Show Highest Rate of Control Ever Observed with Warfarin in Real-world Setting, Surpassing Thresholds for Cost-Effectiveness of Newer Agents Identified in Five Recent Independent Studies
Insufficient medical care of blood clots in the extremities is prevalent, but Dr.
Merck & Co.
Despite the FDA's recent rejection of Xarelto, Dr.
The Firm is investigating testosterone treatment lawsuits on behalf of men who suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious cardiovascular problems,
The Firm is evaluating testosterone treatment lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, deep vein thrombosis, and pulmonary embolism due to their use of
RARITAN, N.J., Feb. 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S.
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.